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DERIVATIVES OF MITHRAMYCIN AND
METHODS OF MAKING AND USES
THEREOF

intermediates With glycosylation steps occurring on the tet
racyclic biosynthetic intermediates. One of the last steps, the

key step in MTM biosynthesis, is the oxidative cleavage of the

fourth ring of the fully glycosylated tetracyclic intermediate
premithramycin B, Which results in the formation of a tricy

CROSS REFERENCE TO RELATED
APPLICATIONS

clic immediate precursor of MTM. FIG. 2 shoWs the rear

rangement of the tetracyclic structure into the tricyclic struc
ture found in MTM. This rearrangement is very important

This application claims the bene?t of priority of Provi
sional Application No. 60/548,175, ?led Mar. 1, 2004 Which

step because it causes an alteration of the shaping of the

molecule. Only the tricyclic structure is biologically active. In
conjunction With the oxidative cleavage step is a decarboxy

is incorporated herein by reference.

lation step that occurs. A pentyl side chain attached at carbon

STATEMENT OF US. GOVERNMENT
SPONSORED RESEARCH

3 is generated, Which plays an important role for the biologi
cal activity of the aureolic acid class of antitumor agents. To
generate the ?nal MTM molecule, the oxidative cleavage step

A portion of this invention Was made With U. S. government
support under a grant from the National Institutes of Health
(NIH), Grant No. RO1CA91901. The government may have

is folloWed by a ketoreduction step, in Which the keto group in
the 4'-position of the 3-side chain is reduced to a secondary
alcohol.
The present invention provides for a mutant Slreplomyces

certain rights in this invention.

Mithramycin (MTM) is an aureolic acid-type polyketide
produced by various soil bacteria of the genus Slreplomyces,

including Slreplomyces argillaceus ATCC 12956 (deposited

20

argillaceus (S. argillaceus M7W1) lacking a nucleic acid that
encodes an active ketoreductase. The mutant S. argillaceus

M7W1 produces mutant derivatives: demycaro syl-mithra

With ATCC, PO. Box 1549, Manassas, Va. 20108 USA).
MTM has the folloWing formula (I):

mycin-SK, mithramycin-SA, mithramycin-SDK and mithra

(1)
CH3

CH3
0

HO HO

HO

B

0

CH3

m0
A

HO

CH3

CH3

CH3

0

HO H3C

o

o
E

D

HO

0

o
0

OH

mycin-SK, the latter being the major product. The derivatives

MTM is the most important representative of the aureolic acid
group of antitumor agents, and is used to treat testicular

are antitumor agents and also act as neuroprotective agents in

carcinoma, Paget’s disease and hypercalcemia caused by

the treatment of neurological diseases.

malignancy-associated bone lesions. MTM is also an agent
for neuroprotection in the treatment of neurological diseases
such as stroke, amyotropic lateral sclerosis, Parkinson’s dis

45

SUMMARY OF THE INVENTION

The invention generally relates to the production of mith
ramycin derivatives from a mutant S. argillaceus M7W 1,

ease, Huntington’s disease, multiple sclerosis and viral

encephalitis.

50

The aureolic acid group of compounds includes MTM,

chromomycin A3 (CHR), olivomycin A (OLI), UCH9, and
durhamycin A. All contain the same tricyclic core moiety
With a unique dihydroxy-methoxy-oxo-pentyl side chain
attached at carbon 3 and vary only slightly, With respect to the
residue at carbon 7, Which is either a H atom or a small alkyl

55

side chain. HoWever, these naturally occurring aureolic acid
antibiotics differ in the nature and linking of their saccharide

chains, Which consist of various 2,6-dideoxysugar residues.
Such structural variations impart subtle differences in the
DNA binding and activity pro?les among the members of this

lacking a nucleic acid that encodes an active ketoreductase.

The present invention also provides for a mutant S. argilla
ceus M7W1 produced by mutating an mtmW gene of Strep
lomyces argillaceus, Whereby the mutated gene does not
encode active ketoreductase.
The present invention further provides a method of making
a mutant S. argillaceus M7W1 comprising mutating an
mtmW gene of S. argillaceus to produce a mutated gene by
insertional mutation of the mtmW gene, Whereby the mutated
gene does not encode active ketoreductase. The mtmW is
mutated ex vivo, and is used to replace the Wild type mtmW

60

group.

gene of Slreplomyces argillaceus.
Finally, the invention relates to mutated organisms useful

in the production of mithramycin derivatives: demycarosyl

The biosynthetic gene cluster leading to the formation of
MTM has been studied and resulted in the identi?cation of 34

mithramycin-SK, mithramycin-SA, mithramycin-SDK and

genes and the assignment of various gene product functions
for the biosynthesis of MTM. FIG. 1 shoWs the gene organi
Zation of the MTM biosynthetic gene cluster in Slreplomyces

mithramycin-SK.

argillaceus. MTM biosynthesis proceeds through tetracyclic

65

Additional advantages of the invention Will be set forth in

part in the description Which folloWs, and in part Will be
obvious from the description, or may be learned by practice of

US 7,423,008 B2
3

4

the invention. The advantages of the invention Will be realized
and attained by means of the elements and combinations
particularly pointed out in the appended claims. It is to be

ther provides a recombinant nucleic acid construct compris
ing a nucleic acid encoding an enzyme to be modi?ed or

deleted by this invention.

understood that both the foregoing general description and
the following detailed description are exemplary and

The nucleic acid sequences can be expressed in hosts, for

example, Slreplomyces argillaceus, after the sequences have
been positioned to ensure the functioning of an expression

explanatory only and are not restrictive of the invention as
claimed.

control sequence. Ho st cells of the present invention are trans

formed and cultured in conventional nutrient media modi?ed
as appropriate for inducing the various promoters if induction
is carried out. “Transformation” means introducing DNA into

BRIEF DESCRIPTION OF THE DRAWINGS

an organism so that the DNA is replicable, either as an extra
chromosomal element or as chromosomal integration.

FIG. 1 is the gene organization of the MTM biosynthetic

gene cluster in Slreplomyces argillaceus.
FIG. 2 shoWs the rearrangement of the tetracyclic rings to

Depending on the host cell used, transformation is done using
standard techniques appropriate to such cells.

form MTM.
FIG. 3 shoWs a non-enzymatic Favorskii-type rearrange

A “cell” can be a cell from any organism including, but not
limited to, a bacterium. Bacterial cells of this invention are
cultured in suitable media in Which the promoters can be

ment in the formation of mithramycin SK and mithramycin
SA.

induced using standard techniques. Any other necessary

FIG. 4 is a schematic representation of the gene replace

ment experiment for generating the mutant S. argillaceus

supplements besides carbon, nitrogen, and inorganic phos

M7Wl.
FIG. 5 shoWs a comparison of the rearrangement of the

phate sources may also be included at appropriate concentra
tions, introduced alone or as a mixture With another supple

20

tetracyclic rings in forming MTM, mithramycin-SK and

ment or medium such as a complex nitrogen source.

mithramycin-SA.

The present invention provides a method of inhibiting
groWth of a tumor, comprising contacting the tumor With a

FIGS. 6A, 6B and 6C are the sequence listing for a gene

compound of the invention. As used herein, “inhibiting”

containing aac(3)IV and mtmW genes (SEQ ID NO: 1).
DETAILED DESCRIPTION OF THE INVENTION

25

The present invention may be understood more readily by
reference to the folloWing detailed description of preferred
embodiments of the invention and the examples included
therein and to the draWing ?gures and their previous and
folloWing description. As used in the speci?cation and the

means decreasing, sloWing or stopping. Thus, a compound of
this invention can decrease, sloW or stop the groWth of a tumor
cell. As used herein, “groWt ” means increase in size or
proliferation or both. Thus, a compound of this invention can
inhibit a tumor cell from becoming larger and/ or can prevent

the tumor cell from dividing and replicating and increasing
30

the number of tumor cells. A “tumor cell” is a cell comprising
a neoplasm (neW groWth), Which can be cancerous (malig

appended claims, the singular forms “a,” “an” and “the”

nant) or non-cancerous (benign). A cancerous tumor cell can

include plural referents unless the context clearly dictates
otherWise. Thus, for example, reference to “a pharmaceuti

invade surrounding normal tissues and blood/lymph vessels

cally acceptable carrier” includes mixtures of tWo or more

35 contrast, a non-cancerous tumor cell can groW and compress

such carriers, and the like.
The gene replacement step of the present invention
involves standard nucleic acid manipulations Well knoWn to

surrounding normal tissue but cannot invade normal tissues
and blood/lymph vessels nor metastasize to tissues distant

and metastasize to tissues distant from the original tumor. In

from the original tumor.

the skilled artisan. “Nucleic acid” as used herein refers to

A cell can be in vitro.Altematively, a cell canbe in vivo and

single- or double-stranded molecules Which may be DNA,
comprised of the nucleotide bases A, T, C and G, or RNA,

can be found in a subject. A “cell” can be a cell from any

40

comprised of the bases A, U (substitutes for T), C, and G. The

organism including, but not limited to, abacterium. As used
throughout, the “subject” can include domesticated animals,
such as cats, dogs, etc., livestock (e.g., cattle, horses, pigs,

nucleic acid may represent a coding strand or its complement.
Nucleic acids may be identical in sequence to the sequence
Which is naturally occurring or may include alternative

rat, guinea pig, etc.) and birds. Preferably, the subject is a

codons Which encode the same amino acid as that Which is

mammal such as a primate, and, more preferably, a human.

sheep, goats, etc.), laboratory animals (e.g., mouse, rabbit,

found in the naturally occurring sequence. Furthermore,

The present invention provides a method of treating cancer

nucleic acids may include codons Which represent conserva
tive substitutions of amino acids as are Well knoWn in the art.
The isolation of nucleic acids can therefore be accom

in a subject diagnosed With cancer, comprising administering

plished by techniques such as cell lysis folloWed by phenol
plus chloroform extraction, folloWed by ethanol precipitation

to the subject an effective amount of a compound of the

invention in a pharmaceutically acceptable carrier, Whereby
50

of the nucleic acids. The nucleic acids of this invention can be

isolated from bacterial cells, for example, Slreplomyces
argillaceus, according to methods Well knoWn in the art for
isolating nucleic acids. Alternatively, the nucleic acids of the
present invention can be synthesized according to standard
protocols Well described in the literature for synthesizing
nucleic acids. Modi?cations to the nucleic acids of the inven
tion, for example, the mtmW gene Which encodes an active
ketoreductase, Will decrease the activity of the enzyme or
block or reduce its synthesis.
A nucleic acid containing a promoter or other regulatory
sequence and/ or encoding a protein (e.g., antibiotic resistance
factor or enzyme) of this invention can be part of a recombi
nant nucleic acid construct comprising any combination of
restriction sites and/or functional elements as are Well knoWn
in the art Which facilitate molecular cloning and other recom

binant DNA manipulations. Thus, the present invention fur

55

the compound treats the cancer in the subject. In general, an
“effective amount” of a compound is that amount needed to
achieve the desired result or results. For example, an effective
amount of a compound of the present invention treats the

cancer by inhibiting the groWth of the cells comprising the
tumor, thereby preventing invasion of normal tissues and
blood/lymph vessels by the tumor cells, thus preventing
metastases. Examples of cancers that can be treated include,

60

but are not limited to, lung, colon, ovarian, prostate, testicular,
melanoma, kidney, breast, central nervous system and leuke
mia. By “pharmaceutically acceptable” is meant a material
that is not biologically or otherWise undesirable, i.e., the
material may be administered to an individual along With the

selected compound Without causing substantial deleterious
biological effects or interacting in a deleterious manner With
65

any of the other components of the composition in Which it is
contained.

The invention is directed to modifying the post-polyketide

synthase (post-PKS) tailoring steps of the mithramycin bio

US 7,423,008 B2
5

6

synthesis by Slreplomyces argillaceus, in particular, the

art. Examples of many of the possible groups can be found in

ketoreductase encoding genes. The ketoreductase step Within
the pentyl side chain attached at carbon 3 to MTM side chain

“Protective Groups in Organic Synthesis” by T. W. Green,
John Wiley and Sons, 1981, Which is incorporated herein by

is the last step of the mithramycin biosynthesis. The mtmW
gene is the enzyme that catalyzes the ketoreduction step

reference in its entirety.
The protecting group comprises, but is not limited to, an
alkyl group, a cycloalkyl group, a heterocyloalkyl group, a

affecting the 3-side chain in the mithramycin biosynthesis.
The mtmW gene is located ca. 8 kb downstream of the

hydroxyalkyl group, a halogenated alkyl group, an alkoxy
alkyl group, an alkenyl group, an alkynyl group, an aryl

mithramycin PKS genes. The gene is replaced by an aac(3)lV
gene that yields a S. argillaceus mutant, Which produces four

group, a heteroaryl group, an aralkyl group, an ester, a car

neW mithramycin derivatives, namely mithramycin-SK,

bonate group, a carboxylic acid, an aldehyde, a keto group, an
ether group, a urethane group, a silyl group, a sulfo-oxo
group, or any combination thereof. In one embodiment, when

demycaro syl-mithramycin-SK, mithramycin- SA, mithramy
cin-SDK. Mithramycin-SK is the major product. The struc
tures of mithramycin- SK and demycaro syl-mithramycin- SK

R1 l in formula (II) is a protecting group, the protecting group

bear a butyl side chain attached at carbon 3 instead of the

expected pentyl side chain With an additional keto function.
This can be explained through a non-enZymatic Favorskii

15

hydroxyl groups in formula (11) may be protected While others
are not. For example, R1, R2, R3, R4, R , R6, R7, R8, R13 and

type rearrangement of the initially formed pentyl side chain
With tWo keto groups in [3-position to each other. FIG. 3 shoWs

R14 may be not protected While R1 1 is protected by an alkyl
group selected from the group consisting of methyl, ethyl,

the non-enzymatic Favorskii-type rearrangement in the for
mation of mithramycin-SK and mithramycin-SA having
structures 2 and 4, respectively, from MTM having structure

is an alkyl group such as methyl, ethyl, propyl, isopropyl,
butyl, isobutyl, or pentyl. In another embodiment, some the

20

propyl, isopropyl, butyl, isobutyl and pentyl.
The protecting groups are removable from the product

5.

compounds of the invention, to regenerate the hydroxyl group
by methods knoWn in the art. Methods for removing protect

The invention contemplates mutant MTM derivatives hav

ing the folloWing general formula (H):

CH3
1

Ro

R60

CH3
0 R30

R20

0

(11)

0

0

R12
OR4

OR5

R80
CH3

40

Wherein

ing groups include, but are not limited to, hydrolysis, hydro
genolysis, treatment With acids or bases, and the like.

R1, R2, R3, R4, R5 , R6, R7 and R8 are each, independently,
hydrogen or a protecting group;
X is C:O or CH(ORU), wherein R11 is hydrogen or a

The stereocenters a, b and c in formula (II) can be R, S or
mixtures thereof. The term “mixtures thereof’ With respect to
the stereochemistry of a-c, When considered With stereo

protecting group;
R10 is OH When X is C:O or C(O)CH3 When X is

CH(ORU);

center d, includes all possible diastereoisomers and enanti
omers of formula (II). A compound having the formula (II)

R9 is hydrogen, a protecting group or
50

can be a racemic mixture or exist as an enantiomeric excess of

a particular stereochemistry. Alternatively, a compound hav
CH3

ing the formula (II) can exist as tWo or more diastereoisomers.

R140
55

ORB

the stereochemistry at carbons a, b and c is R, S or mixtures
of d is R or S.
One or more of the hydroxyl groups present in the mutant
derivative can be protected With a protecting group. The term
“protecting group” is de?ned herein as a group that is used to
replace hydrogen of a hydroxyl group to produce a neW

group. Various protecting groups useful in the invention and
methods for their synthesis and removal are Well knoWn in the

having the formula (II) can be enantiomerically pure.

Using techniques known in the art, it is possible to epimer
iZe the stereocenters a-d. A compound having the formula (II)

R12 is methyl or hydrogen; and

thereof, and When X is CH(ORU), the stereochemistry

For example, the stereochemistry at carbons a, b and c are S
and the stereochemistry at carbon d is R or the compounds

60

can be treated With a base in order to produce a racemic or

diastereomeric mixture. Also, the use of a chiral auxiliary in
combination With a base can be used to selectively convert
stereocenters a-d from one stereoisomer to the other.

The mutant S. argillaceus M7Wl produces ?ve neW
65

derivatives of MTM: mithramycin-SK, demycarosyl-mithra

mycin-SK, mithramycin-SA and mithramycin-SDK. Mithra
mycin-SK has the folloWing formula (III):

US 7,423,008 B2

(111)

CH3

CH3
HO H3C

CH3

CH3

O

O

OH

In a preferred embodiment, the stereochemistry at carbons a, 20
b and c is S and the stereochemistry at d is either R or S. The

methyl group on the ?rst aromatic ring of mithramycin-SK
can be a H, thereby providing another derivative of formula

(III).
Demycarosyl-mithramycin-SK has the following formula 25

(IV):

(1V)
CH3
HO HO

CH3

0H

CH3

CH3
HO

HO

O

Mithramycin-SA has the folloWing formula (V):
50

(V)

OH

CH3

60

CH3

CH3
HO

OH
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Mithramycin-SDK has the following formula (VI):

(V1)

CH3

CH3

HO

0

H3C
OH

The method for making and isolating derivatives mithra

mycin-SK, mithramycin-SA, demycarosyl-mithramycin
SK, and mithramycin-SDK, generally involves (i) incubating

30

the mutant S. argillaceus M7W1, (ii) forming a composition
and (iii) isolating the derivatives from the composition. The
incubation time and temperature Will vary depending upon
the amount of mutant that is employed. The incubation tem
perature is generally from 25° C. to 40° C., from 30° C. to 35°

C., and preferably 30° C. The incubation time ranges from
generally several hours to several days, e.g., from 1 to 10
days, 2 to 9 days, 3 to 8 days, 4 to 7 days, and 5 to 6 days.
The mutant S. argillaceus M7W1 is generally incubated in
a solution. An example of a solution useful includes, but is not
limited to, a broth containing the minimal factors required for
S. argillaceus M7W1 survival or groWth. After incubation,

35

The derivatives can be further puri?ed using techniques

DNA sequencing Was performed on double- stranded DNA
40

analyses Were conducted using the University of Wisconsin
45

A schematic representation of the gene replacement pro
cedure generating mutant S. argillaceus M7W1 is shoWn in
FIG. 4. The 1.4 kb region of the mtmW gene is located
50

The mutant S. argillaceus M7W1 is prepared in the folloW
ing manner. Slreplomyces argillaceus ATCC 12956 Was used
55

When plasmid-containing clones Were groWn, the medium

Was supplemented With the appropriate antibiotics: thiostrep

deposited at the EMBL bank (European Molecular Biology
Laboratory, Meyerhof Strasse 1, 69117 Heidelberg, Ger
many) on Apr. 29, 2002, With the accession number
AJ459240.
The mtmW gene is comprised of 981 nucleotides With a
GTG start codon and a TAG stop codon and codes for a
polypeptide of 326 amino acids With an estimated Mr of 35

medium (trypticase soya broth, Oxoid). Escherichia coli
ods of preparation and transformation of Slreplomyces
argillaceus protoplasts are taught by T. Kieser et al., in “Prac
tical Slreplomyces Genetics,” published in 2000 by the John
Ines Foundation of NorWich, England. This reference is
incorporated herein in its entirety.

betWeen several sugar biosynthetic genes (mtmV, mtmU,
mtmC, and mtmTSl) and glycosyltransferase genes (mtm
GIV and mtmGlll). The sequence of the mtmW gene has been

as the source of chromosomal DNA. For sporulation on a

XLlblue Was used as the host for plasmid propagation. Meth

Genetics Computer Group programs package (UWGCG) and
the BLAST program.

Generation of the Mutant S. argillaceus by Gene

solid medium, it Was groWn at 30° C. on plates containing
medium A. For protoplast transformation, it Was groWn in a
YEME medium containing 17% sucrose. For groWth in a
liquidmedium, Slreplomyces argillaceus Was groWn in a TSB

method. Both DNA strands Were sequenced With primers
supplied in the kits or With internal oligoprimers (17-mer)

using anALF-express automatic DNA sequencer (Pharmacia
Biotech). Computer-aided database searching and sequence

knoWn in the art.

Replacement

plAGO, and pEFBA Were used (the pEFBA plasmid is a
pBSK derivative containing an apramycin resistance cassette;
pBSK can be obtained from Stratagene, 11011 M. Torrey
Pines Road, La Jolla, Calif.). Plasmid DNA preparations,
restriction endonuclease digestions, alkaline phosphatase
treatments, ligations, Southern hybridiZation, and other DNA
manipulations Were performed according to standard proce
dures for E. coli and Slreplomyces.

templates using the dideoxynucleotide chain-termination

the composition is centrifuged, and the supernatant is applied
to a solid-phase extraction cartridge to isolate the derivatives.

ton, 25 ug/mL; tobramycin, 20 ug/mL; ampicillin, 100
ug/mL; or apramycin, 25 ug/mL. Plasmids pBSKT, pl] 2921,

60

304. This codon region shoWs the high GC content and bias
for the third codon position, Which is characteristic of Strep
lomyces genes. Comparison of the deduced product of mtmW

With other proteins using protein databases revealed similari
ties With various oxidoreductases. The highest similarities
65

Were observed With a putative potassium channel beta subunit

of Deinococcus radiodurans (40% identical amino acids). It
also shoWed similarity With the EryBll (33% identical amino

US 7,423,008 B2
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12

acids) and TyICII (33% identical amino acids) proteins.

?asks Were incubated for 5 days under the previously

These tWo proteins are oxidoreductases, Which participate in

described conditions. The entire culture obtained Was centri

deoxygenation steps during the biosynthesis of the deoxysug

fuged (12,000 rpm, 30 minutes), the pellets Were discarded,

ars that form part of the macrolide antibiotics erythromycin

and the supernatant Was ?ltered using membrane ?lters With

and tylosin, respectively.

a pore siZe of 0.45 pm. The ?ltrate Was applied to a solid

phase extraction cartridge (Supelclean LC-18, 10 g, Supeico),

The mtmW is inactivated by gene replacement through the

and the retained material Was eluted With a mixture of metha

insertion of an apramycin resistance cassette. To inactivate
the mtmW gene, a 4.5 kb BamHI fragment containing

nol and Water. A linear gradient from 0% to 100% methanol
over 60 min, at 10 mL/min, Was used.

mtmW, mtmGlV, and portions of adjacent genes is subcloned
into the BamHI site of pBSKT, generating M7W0. Upon
transformation of the Wild-type Slreplomyces argillaceus

Fractions Were taken every 5 minutes. The neW derivatives
Were found in fractions eluted betWeen 40 and 55 minutes.
These fractions Were evaporated under vacuum, redissolved

ATCC 12956 With pM7W1, transformants Were selected for
their resistance to apramycin. An apramycin resistance cas
sette containing the aac(3)IV gene Was subcloned as a 1.5 kb

in a mixture of dimethyl sulfoxide and methanol (50: 50), and

SmaI-EcoRV fragment into the unique Bg/II site (blunt

chromatographed using a uBondapak C18 preparative col

ended) located Within the coding region for mtmW and ori
ented in the direction of transcription of mtmW, thus gener
ating mutant S. argillaceus M7Wl.

umn (PrepPak Cartridge, 25 mm><100 mm, Waters), With

The aac(3)IV gene is deposited at Gen Bank having acces
sion numbers X01385 and V01499. The sequence listing
containing the aac(3)IV and mtmW genes is set forth in FIG.
6 as SEQ ID NO: 1. Nucleotides 1416 to 4221 of SEQ ID
N011 represent the mutated mtmW gene While nucleotides
2104-3608 of SEQ ID NO:1 represent the aac(3)IV cassette.
This construct, pM7W1, Was used to transform protoplasts of
Slreplomyces argillaceus, and these transformants Were
selected for resistance to apramycin. Any antibiotic resistance

acetonitrile (ACN) and Water as solvents, at a ?oW rate of 10
20

isocratic conditions With 37.5% ACN in Water as a solvent.

The isolated products Were ?nally dried in vacuo and
25

Weighed. TWo compounds isolated and puri?ed Were mithra

mycin-SK and demycarosyl-mithramycin-SK, the mithra

mycin-SK being the major product produced.
An alternative procedure via liquid extraction and conven
30

gene can be used provided that it can be selected for resistance

tional chromatography yielded mithramycin-SA in addition
to mithramycin-SK and demycarosyl-mithramycin-SK. The
procedure is described as folloWs. A seed culture Was pre

in Slreplomyces argillaceus. Examples include, but are not

limited to, erythromycin, hygromycin, thiostrepton, specti
nomycin, viomycin and kanamycin.

mL/min. A linear gradient from 30% to 50% ACN in 30
minutes Was used. The elutant Was further puri?ed under

pared using TSB inoculated With spores of S. argillaceus
35

M7W1 and incubated in an orbital shaker for 24 hours at 30°
C. and 250 rpm. This seed culture Was used to inoculate (at 2.5

v/v) sixteen 250-mL Erlenmeyer ?asks, each containing 100
To verify that gene replacement occurred, the transfor
mants Were tested for their susceptibility to thiostrepton. The

Wild-type region of the chromosome Was replaced by the in

40

vitro mutant S. argillaceus M7W1 through a double crossover
at both sides of the apramycin cassette. The mutant S. argilla
ceus M7W1 is sensitive to thiostrepton, the consequence of a

double crossover, Which results in the replacement of the
Wild-type gene by the in vitro mutated one. This fact Was

mL of modi?ed R5 medium. Thirty-tWo hours after the inocu
lation, a pulse feeding of sodium acetate Was started and
continued for 36 hours at 12 hour intervals (four feedings for
a total of 1 g of sodium acetate per liter of culture). The culture
Was then groWn for an additional 52 hours, for a total of 120

45

hours before extraction. Following acidi?cation With HC1 to
pH 5.5, the culture Was extracted ?rst With EtOAc and then
With BuOH.

con?rmed by Southern hybridiZation: the 4.5 kb BamHl frag
ment of the Wild-type strain Was replaced by tWo neW BamW

The more-lipophilic compounds, mithramycin-SK (yield

fragments of 3.7 and 2.3 kb, as expected if the replacement
occurred. It Was also con?rmed that the gene replacement

of 13.7 mg) and demycarsoyl-mithramycin-SK (yield of 3.2
50

only affected mtmW, because expressing this gene in trans,
using pAGW, restored MTM production in mutant S. argilla

found in the n-BuOH extract. Silica gel chromatography Was
used for both the EtOAc extract and the n-BuOH extract.

ceus M7Wl.
55

Production and Isolation of Mithramycin-SK,

Mithramycin-SA and Demycarosyl-Mithramycin-SK
The derivatives mithramycin-SK, mithramycin-SA and

meyer ?asks, each containing 400 mL of R5A medium. The

Mithramycin-SK and demycarosyl-mithramycin-SK Were
puri?ed using an RP-18 silica gel column, folloWed by
Sephadex-LH 20 chromatography. Mithramycin-SA Was

puri?ed through preparative thin-layer chromatography
60

demycarosyl-mithramycin-SK Were prepared in the folloW
ing manner. A seed culture Was prepared using TSB inocu
lated With spores of S. argillaceus M7W1 and incubated in an
orbital shaker for 24 hours at 30° C. and 250 rpm. This seed
culture Was used to inoculate (at 2.5% v/v) eight 2-liter Erlen

mg), Were found in the EtOAC extract, Whereas the more

hydrophilic mithramycin-SA (yield of 4.8 mg) Was solely

(TLC), using RP-18 silica gel plates. The exact isolation
procedure is described Remsing et al., J. Am. Chem Soc., Vol.
125, No. 19, pp. 5745 to 5753 Which is incorporated herein by
reference.
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An analog of mithramycin-SK having the folloWing for
mula (VII) can be produced from mutant S. argillaceus
M7W1:

US 7,423,008 B2
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(V11)
HO HO

cH3

0H

CH3

cH3

CH3
Ho

Ho H3C
OH

This compound can be prepared by inactivating the respec
tive methyltransferase gene in S. argillaceus M7W1. The

Drug Mithramycin by Slreplomyces Argillaceus, Reveal

20

Novel Insights into Post-PKS Tailoring Steps of the Mithra
mycin Biosynthetic Pathway”, .1. Am. Chem Soc., Vol. 124,
No. 8, 1606-1614 (2002), Which are incorporated by refer

techniques inactivating the respective methyltransferase gene
are disclosed in FemandeZ-LoZano et al. in “Characterization

of TWo Polyketide Methyltransferases Involved in the Bio

synthesis of the Antitumor Drug Mithramycin by Streptomy

ence in their entireties. The methyltransferase gene S. argilla
ceus M7W 1 can be mutated prior to or after the mutation of

25

Obtained upon Inactivation of TWo Genes Involved in the

the mtmW gene S. argillaceus M7W 1.
Mithramycin SK has a molecular formula of CSIHMO23
and a molecular Weight of 1054.4. The 1H-NMR and 13C
NMR data are provide in Table 1 and based on the folloWing

Biosynthesis of the Deoxysugar Moieties of the Antitumor

labeling scheme:

ces argillaceus,”.]. Biol. Chem. 200, 275, 3065-3074 (2000),
and Remsing et al. in “Ketopremithramycins and Ketomith

ramycins, Four NeW Aureolic Acid-Type Compounds

TABLE 1

cH3
Ho
Ho

cH3
0 Ho

0
0

B

1B

3A

A

0
1A

Ho

cH3
OH

lH-NMR (acetone-d6, 400 MHZ) and l3c-NMR (acetone-d6, 100 MHZ) Data
for Mithramycin-SK

Position
1

2
3
4,
46
4a

1H 6 (ppm)

Multiplicity, 1 (Hz)

i

i

4.7
2.48
3.15
2.99

d (11.5)
overlap
dd (16, 3)
overlap

13C 6 (ppm)
78.18
43.71
28.3
28.3

i

i

5

6.87

S

101.7

6

i

i

159.9
111.0

7

i

i

S

8

i

i

156.2

7.91

8a

i

i

108.0

9

i

i

165.3

9a

i

i

108.5

6.89

S

117.0

i

i

139.1

10
10a

1'

dd(3.4, 1.5)

10, 3, 4,, 4e, 1'
2, 4a, 4e, 1', 2'
2,10,1',2'

136.9

2.15

7-CH3

HMBC

203.5

79.28

1'—OCH3

US 7,423,008 B2
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2H, 5-H, and 10-H). l3C-NMR (125.7 MHZ, acetone-d6, 6):
7.9 (7-CH3), 16.5 (C-6D), 17.6 (C-6B), 17.9 (C-6C and
C-6A), 26.2 (C-4'), 28.3 (C-4), 35.2 (C-2D), 37.5 (C-2A),
37.9 (C-2C), 40.0 (C-2B), 43.8 (C-3), 60.0 (1'-OCH3), 68.9
(C-3D), 70.2 (C-4D), 71.3 (C-5D), 72.7 (C-5A and C-5C),
75.4 (C-4A), 75.7 (C-4C), 77.5 (C-4B), 78.1 (C-2), 79.30
(C-1'), 79.5 (C-2'), 81.3 (C-3A), 81.7 (C-3C), 97.1 (C-1A),
99.9 (C-lB), 100.4 (C-1D), 100.8 (C-1C), 101.7 (C-5), 108.0
(C-8a), 108.6 (C-9a), 111.1 (C-7), 117.1 (C-10), 137.0
(C-4a), 139.1 (C-10a), 156.1 (C-8), 160.0 (C-6), 165.4 (C-9),
203.6 (C-1) and 209.8 (C-3').

TABLE 2
1H-NMR (pyridine-d5, 400 MHZ) and l3c-NMR (pyridine-d5,
100 MHZ) Data for Mithralnvcin SDK

Multiplicity
Position

2
3

4.87
3.09

4ax
4eq

3.27
2.85
4

HMBC

7.09

4

d (12)
dddd(12,12,3,1)

204.3

f

(brdd, 16,12)
dd (16, 3)

78.0
43.6

28.4

4

136.6

S

100.9

25

7, 8a, 10

i

4

160.3

f

i

4

111.5

f

2.44

S

9.4

6, 8

8

i

4

157.4

4

8a

4

4

109.6

f

9

i

4

166.8

4

9a

4

4

109.6

f

10

6.70

br. S

117.4

5, 8a, 9a, 4

4

139.5

f

4

1'

5.49

d (1)

83.5

2, 4, 4OCH3,

1'-

3.72

S

59.7

1'

OCH3
2'

i

4

198.6

f

3'

i

4

199.5

f

4'

2.42

S

26.4

2'

6

SugarA ([3-D-olivose)
30

1A

5.62

dd (10, 2)

98.4

2Aax

2.16

ddd(12,12, 10)

37.4

2Aeq
3A
4A

2.51
4.54
3.43

m (overlap)
ddd (12, 9, 5)
dd (9, 9)

81.3
75.4

5A

3.55

m (overlap)

72.6

6A

1.56

d (6)

18.0

1B

Sugar B ([3-D-olivose)

35

1B

5.56

dd (10, 2)

2B,X

2.04

ddd(12,12, 10)

100.2

3A

40.0

2Beq

2.46

m (overlap)

3B

4.44

m (overlap)

71.4

4B
40
SE

3.33
3.41

dd (9, 9)
dq (9, 6)

77.6
72.6

6B

1.45

d

17.7

Sugar C ([3-D-olivose)
1C
2C,X

5.39

1.80

dd (10, 2)
ddd(12,12,10)

100.8

2

37.9

2Ceq

2.95

ddd (12, 5, 2)

3C

4.09

m (overlap)

81.8

4C
5C
6C

3.47
3.65
1.38

dd (9, 9)
dq (9, 6)
d (6)

75.7
72.6
17.9

1D

4.74

dd (10, 2)

2D,X

1.79

ddd(12,12,10)

2.43

ddd (12, 5, 2)

1D

Sugar D ([3-D-oliose)
50

2Deq

100.3

3C

32.5

3D

3.98

ddd (12, 5, 3)

77.3

4D
55 SD

3.53
3.63

br. S
m (overlap)

68.9
71.0

6D

1.39

d (6)

16.5

by Washing the column With acetonitrile:Water (5:95). Three

1E

Sugar E (?-D-macarose)

fractions Were collected eluting With ACN:Water mixtures

60

1E

5.34

dd (9.5, 2)

97.9

2E,X

2.34

dd (13, 9.5)

44.3

2Eeq

2.46

3E

i

3D

dd (13, 2)
i

70.7

by a reverse phase column (15x15 cm, ACN:Water 33:67),

3E-CH3
4E

1.93
3.09

S
d (9)

27.0
76.8

yielding 28.4 mg mithramycin-SDK.

SE

4.65

m (overlap)

71.0

Mithramycin-SDK has a molecular formula of C5 lH72023
and a molecular Weight of 1053.1. The 1H-NMR and 13C

6E

1.57

d (6)

17.7

labeling scheme as for Mithramycin-SK:

2,10,9a,1
2, 9a, 1'
f

6

10a

media for ?ve days. The cultured media Was centrifuged at

NMR data are provide in Table 2 and based on the same

1C, 4, 9a
1, 4a, 2'

20

culture Was used to inoculate (at 2.5%, v/v) tWenty 250 ml
Erlenmeyer ?asks, each containing 100 ml of modi?ed R5

and increasing the ACN partition: fraction 1 (20% ACN)
contains mithramycin-SA, fraction 2 (25% ACN) contains
mithramycin-SK, and fraction 3 (31% acetonitrile) contains
mithramycin-SDK. Fraction three (F3) Was further puri?ed

Important 3]

7

7-CH3

A seed culture Was prepared using TSB inoculated With

a reverse phase column (45x10 cm) With pressure folloWed

i

5

Production and Isolation of Mithramycin SDK

4,000 rpm for 30 minutes and the supernatants passed through

1

4a

45

spores of the S. argillaceus M7W1 mutant and incubated in an
orbital shaker for 24 hours at 30° C. and 195 rpm. This seed

6 13C
(ppm)

Aglycon

Mithramycin SA has a molecular formula of C49H7OO23
and a molecular Weight of 1049.4, and has the 1H-NMR and

l3C-NMR data: 1H-NMR (400 MHZ, pyridine-d5, 6): 1.50 (s,
3H, 3E-CH3), 1.52 (d, 3H, 1:65 HZ, 6E-H3), 1.62 (d, 9H,
1:60 HZ, 6A-H3, 6CiH3, and 6D-H3), 1.68 (d, 3H, 1:60
HZ, 6BiH3), 1.77 (bt, 2H, 1:100 HZ, 2E-Ha, and 2BiHa),
1.92 (bdd, 1H, 1:12, 9 HZ, 2CiHa), 2.02 (bdd, 1H, 1:12, 11
HZ, 2D-Ha), 2.08-2.22 (overlap, 2H, 2A-Ha, and 2D-Ha, and
2D-He), 2.28 (dd, 1H, 1:9, 2 HZ, 2E-He), 2.38 (bd, 1H, 1:10
HZ, 2A-He), 2.47 (s, 3H, 7-CH3), 2.54 (m, 1H, 2CiHe), 2.79
(m, 1H, 2B-Hc), 2.93(m, 1H, 4-He), 3.11 (bt, 1H, 1:152 HZ,
4-Ha) 3.14(bt, 1H, 1:11 HZ, 3-H), 3.36 (d, W,J:9 HZ, 4E-H),
3.49-3.72 (overlap, 4H, 3A-H, 3BiH, 3CiH, and 5A-H),
3.55 (dd, 1H, 9, 8.5 HZ, 4CiH), 3.62 (s, 3H, 1'-OCH3), 3.84
(bdd, 1H, 1:120, 4.5 HZ, 3D-H), 3.93-4.02 (overlap, 4H,
4A-H, 4BiH, 4D-H, 5CiH, and 5D-H), 3.98 (dq, 1H,
1:100, 6.0 HZ, 5E-H), 4.29 (dq, 1H, 1:100, 6.0 HZ, 5BiH),
4.76 (bd, 1H, 1:10 HZ, lD-H), 4.86 (d, 1H, 1:15 HZ, 1'-H),
4.92 (d, 1H, 1:11 HZ, 2-H), 5.00 (dd, 1H, 1:10, 2 HZ lBiH),
5.41 (dd, 1H, 1:10, 2 HZ, lCiH), 5.53 (dd, 1H, 1:10, 2 HZ,
lE-H), 5.61 (dd, 1:10, 2 HZ, lA-H), 6.61 (s, 1H, 10-H), and
7.01 (s, 1H, 5-H). l3C-NMR (75.4 MHZ. methanol-d4, 6): 7.1
(7-CH3),15.9 (C-6D), 17.1 (C-6B), 17.3 (C-6C), 17.4
(C-6A), 18.0 (C-6E), 26.3 (3E-CH3), 29.7 (C-4), 32.3
(C-2D), 37.1 (C-2A), 37.5 (C-2C), 39.7 (C-2B), 44.6 (C-2E
and C-3), 59.6 (1'-OCH3), 68.7 (C-4D), 70.7 (C-3E and
C-5E), 70.9 (C-3B and C-5D), 72.5 (C-5C and C-5B), 72.9
(C-5A), 75.1 (C-4A), 75.7 (C-4C), 76.2 (C-3D), 76.8 (C-4E),
77.0 (C-2 and C-4B), 79.5 (C-3A), 81.5 (C-3C), 82.2 (C-1'),
97.5 (C-1A) 97.6 (C-1E), 98.8 (C-lB and C-1D), 100.0
(C-1C), 100.1 (C-5), 108.0 (C-8a), 108.6 (C-9a), 111.7 (C-7),
117.2 (C-10), 138.5 (C-4a), 138.7 (C-10a), 159.2 (C-6), 160.5
(C-8), 165.0 (C-9), 176.8 (C-2') and 198.4 (C-1).

6 1H (ppm) J (HZ)

2E, 4E
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In FIG. 3, mithramycin-SA structure 4 gives indirect evi
dence for the labile MTM structure 5, because its formation

US 7,423,008 B2
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from 5 is possible through the attack of water at the carbonyl
adjacent to the methoxy group, followed by retro-aldol cleav
age to yield mithramycin- SA structure 4 and hydroxyac
etone. To prove the excision of carbon 3', two feeding experi
ments using [1-13C]-acetate and [1,2-13C2]-acetate were

Mithramycin

Concentration

Lung

Breast

CNS

performed.

Compound

(molar)

(NCI-H460)

(MCF-7)

(SF-268)

Premithrarnycin

1 x 104"6

68

not tested

TABLE 3
Proliferation Inhibition Assays — Percent Growth in 48 Hours

FIG. 5 shows the results of incorporation experiments with

[1-l3C]-acetate and [1,2-13C2]-acetate on the mithramycin
SK and mithramycin-SA produced from S. argillaecus
M7W1, compared to the normal incorporation pattern found

Ar

in mithramycin. In FIG. 5, R and R' are the deoxysaccharide

Mithrarnycin-SK

1>< 10*5

0.1

Demycarosyl-

1 x 10’5

5

>100
12

>100
not tested

0.2

1

22
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The cytotoxicity of Mithramycin-SK and demycarosyl

gers a Favorskii-like rearrangement, for which an 1,2-acyl

molar. Cell lines were inoculated into a series of 96-well
20

microliter plates with varying seeding densities depending on
the growth characteristics of the particular cell lines. Follow
ing a 24 hour drug-free incubation, mithramycin-SK was

The oxidative rearrangement during the bio synthesis of

added routinely at ?ve 10-fold dilutions with maximum con
centration of 10.4 M. After 48 hours of drug exposure, the

MTM leads to an acetate incorporation pattern as shown in

with these expectations and, thus, prove the loss of carbon 3'.

>100
12

mithramycin-SK were assessed in a panel of 60 cell lines
using a sulforhodamine B assay. It is active against a variety
of tumor cell lines in the concentration range of 10-5 to 10-8

formation of mithramycin-SK and mithramycin-SA, respec
tively. It is believed that the [3-dicarbonyl constellation trig

FIG. 5, wherein carbons 4' and 5' of the carbon 3 side chain
stem from the starter unit, whereas carbons 1', 2', and 3' were
once the end of the polyketide chain. If carbon 3' is lost, two
intact acetate units facing each other from opposite directions
should result. The results, also shown in FIG. 5, are consistent

1 x 10’5
1 x 10’5

Mithramycin-SK

chains shown in formulas (III) and (V). The comparison
reveals that the former mithramycin carbon carbon 3' and
carbons 3', 4' and 5' respectively, were excised during the

shift induced by deprotonation of the central alcohol can be
envisaged, followed by the addition of water on the resulting
aldehyde and a consequent departure of formic acid.

Premithrarnycin B
Mithramycin

93

25

change in protein stain optical density allowed the inhibition
of cell growth to be analyZed.
Mithramycin-SK and demycarosyl-mithramycin-SK were

30

also tested in a neutral red toxicity assay. In this experiment,
non-tumorous mouse ?broblast cells were used (NIH 3T3).
After 24 hours of incubation, Mithramycin-SK showed no

toxicity even at 200 ug/mL, while the revealing antiprolifera

Biological Activity
The mithramycin SK has antitumor activity substantially
higher than that of MTM and is particularly active against

tive activity in concentrations <1 ug/mL.
Compilation of the average log(GI5O) values showed that
both compounds were active, with mithramycin- SK (activity
35

active than demycarosyl-mithramycin-SK (ca.25 times less
active than MTM). Mithramycin-SK was particularly active
against melanoma, leukemia, and CNS cancer cells (log
(GI50) values of —7.64, —7.59, and —7.61, respectively).

melanoma, leukemia and CNS cancer cells. Moreover, initial

in vitro anticancer assays, pursued by the NCI (National
Cancer Institute, Bethesda, Md.) against 60 human cancer
cell lines, as well as an in vitro toxicity assay generated
promising results in that mithramycin-SK showed an up to
two orders of magnitude better antitumor activity and a two

40

Given the increased activity observed for mithramycin-SK, a

neutral red uptake analysis of squamous, melanoma, lung,
and breast carcinomas was performed, which not only con

orders of magnitude lesser toxicity than the parent compound

?rmed the increased activity of mithramycin-SK as compared

MTM itself.

Table 3 shows IC5O values (pg/kg) of active extracts of the
cancer cells. The experiment was performed by Biotecon,
Berlin. It measures the uptake of sulforhodamin B (SRB),
which is dependent on the cellular protein quantities, and can
be performed in 96-well microtiter plates according to the
protocol published by Boyd et al. (NCI). The SRB assay is a
rapid and sensitive method to measure drug-induced cytotox
icity. Brie?y, cells will be incubated with and without drug for
72 hours (drugs will be added after 24 hours), ?xed with TCA
(trichloroacetic acid), and stained for 30 minutes using a
0.4% (w/v) SRB solution in 1 acetic acid. Cultures will then
be rinsed with 1% acetic acid, residual wash solution will be
removed and air-dried. Bound dye will be solubiliZed with 10
mM unbuffered Tris base (pH 10.5) for 5 min., and the optical
density (OD) will be measured with amicrotiter plate reader
at 564 nm. (Skehan, P. et al., “New calorimetric cytotoxicity

up to 9 times higher than that of MTM) being much more

to MTM, but also showed an even more pronounced improve
45

ment of activity (up to ca. 90 times better). In addition, tox
icity assays using this same process and mouse 3T3 ?broblast
(nontumor) cells showed that 2, with an IC5O value of 1.96><
10'5 M, is more than 1500-fold less toxic than MTM (IC5O

values ranging from 1.29><10_8 to 3.45><10_9 M). Thus, mith
50

ramycin-SK displays a signi?cantly improved therapeutic
index, up to 4 orders of magnitude better when compared to
its parent compound, MTM. The results are shown in Table 4.
TABLE 4

55

Antitumor Analysis Comparing Mithramycin (l), Mithramycin SK (2),
and Demycarosyl-Mithrarnycin-SK (3).
Composition with 2
60 Type ofCancer

1

2

ing the growth of cancer cells in lung, breast and CNS cells
when compared to other anti-cancer compounds at the same
concentration.

AIF“

3

AH

AIF

Average Log(GI5O) Values

assay for anticancer-drug screening,” Journal ofthe National
Cancer Institute, 1990. 82(13): p. 1107-1112). The data indi
cate that mithramycin-SK was much more effective in reduc

AH

Composition with 3

from Sulforhodarnine B Assay
Leukemia (5)b
NSCLC (8)b
65 Colon (7)b
CNS (5)b

—6.65
—6.73
—6.65
—6.78

—7.59
—7.37
—7.32
—7.61

0.94
0.64
0.67
0.83

8.7
4.4
4.7
6.8

—5.55
—5.30
—5.35
—5.30

—1.10
—1.43
—1.30
—1.48

0.08
0.04
0.05
0.03

US 7,423,008 B2
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composition. Pharmaceutical compositions may include car

riers, thickeners, diluents, buffers, preservatives, surface

TABLE 4-continued

active agents and the like in addition to the molecule of
Antitumor Analysis Comparing Mithramycin (1), Mithramycin SK (2),

choice. Pharmaceutical compositions may also include one or
more active ingredients such as antimicrobial agents, antiin

and Demvcarosvl-Mithramvcin-SK (3).
Composition with 2

Type ofCancer

1

2

Melanoma(8)b
Ovarian(6)b
Renal(8)b
Prostrate(2)b
Breast (8)b

—6.72
—6.60
—6.73
—6.90
—6.59

A172

—7.64 0.92
—7.53 0.93
—7.29 0.56
—7.48 0.58
—5.89 —0.70

?ammatory agents, anesthetics, and the like.

Composition with 3

AIF“

3

A13

AIF

8.3
8.5
3.6
3.8
0.2

—5.37
—5.23
—5.14
—5.25
—5.15

—1.35
—1.37
—1.59
—1.65
—1.44

0.04
0.04
0.03
0.02
0.04

The compounds of the invention may be administered to
the subject in a number of ways depending on whether local
or systemic treatment is desired, and on the area to be treated.
10

the surface of the eye. Moreover, a compound can be admin

istered to a subject vaginally, rectally, intranasally, orally, by
inhalation, or parenterally, for example, by intradermal, sub
cutaneous, intramuscular, intraperitoneal, intrarectal, intraar
terial, intralymphatic, intravenous, intrathecal and intratra
cheal routes. Parental administration, if used, is generally
characterized by injection. Inj ectables can be prepared in

Average Log(GI5O) Values
from Neutral Red Assay
Squamous carcinoma

—5.04 —5.99

Melanoma

—5.05 —6.25

Lung carcinoma

—4.92 —6.88

Breast carcinoma

—4.95 —6.74

0.95
1.20
1.96
1.79

8.9
15.8

91.2
61.6

“Activity improvement factor. This factor is equal to 10M“, Where x is the
identifying value for compound 2 or 3. An AIF of 1.0 corresponds to no dif

Thus, for example, a compound of the present invention can
be administered as an ophthalmic solution and/ or ointment to

20

conventional forms, either as liquid solutions or suspensions,
solid forms suitable for solution or suspension in liquid prior
to injection, or as emulsions. A more recently revised

ference in activity.
bThe number in parenthesis is the number of cell lines tested in each family.

approach for parenteral administration involves use of a slow
release or sustained release system such that a constant dos

The data in Table 4 shows that mithramycin-SK (compound
2) exhibits an activity that is up to 90 times higher than MTM

age is maintained. See, e.g., US. Pat. No. 3,610,795, whichis
25

(compound 1).

aqueous or non-aqueous solutions, suspensions, and emul
sions which may also contain buffers, diluents and other
suitable additives. Examples of non-aqueous solvents are

Therapeutic Administration of the Mithramycin
Derivatives
30

The dosages or amounts of the compounds of the invention

emulsions or suspensions, including saline and buffered
media. Parenteral vehicles include sodium chloride solution,

as to cause adverse side effects, such as unwanted cross
35

dosage will vary with the age, condition, sex and extent of the
disease in the subject and can be determined by one of skill in

nutrient replenishers, electrolyte replenishers (such as those
based on Ringer’s dextrose), and the like. Preservatives and
other additives may also be present such as, for example,
40

be varied. Doses and dosing regimens used form Mithramy
cin provide guidance for dose and dosing regimens for Mith
ramycin SK (see for example Trask and Sonhami, “Effect of
Mithramycin on Widespread Painful Bone Metastases in
Cancer of the Breast,” Cancer Treat. Rep, 63(11-12): 1835
1838 (1979); and Conrad et al., “Mithramycin in the Treat

Ringer’s dextrose, dextrose and sodium chloride, lactated
Ringer’s, or ?xed oils. Intravenous vehicles include ?uid and

the art. The dosage can be adjusted by the individual physi
cian based on the clinical condition of the subject involved.
The dose, schedule of doses and route of administration may

propylene glycol, polyethylene glycol, vegetable oils such as
olive oil, and injectable organic esters such as ethyl oleate.
Aqueous carriers include water, alcoholic/ aqueous solutions,

are large enough to produce the desired effect in the method
by which delivery occurs. The dosage should not be so large

reactions, anaphylactic reactions, and the like. Generally, the

incorporated by reference herein.
Preparations for parenteral administration include sterile

antimicrobials, anti-oxidants, chelating agents, and inert
gases and the like.
Formulations for topical administration may include oint

ments, lotions, creams, gels, drops, suppositories, sprays,
liquids and powders. Conventional pharmaceutical carriers,
45

aqueous, powder or oily bases, thickeners and the like may be
necessary or desirable.

ment ofSystemic Mastocytosis,”Ann. Intern. Med., 83(5): 65

Compositions for oral administration may include powders

9-660 (1975)). For example, a single or multiple dose can be
administered. In one embodiment, the dosages can be in
ranges from 0.1 to 100 mg/kg, 0.1 to 90 mg/kg, 0.1 to 80
mg/kg, 0.1 to 70 mg/kg, 0.1 to SOmg/kg, 0.1 to 20 mg/kg, 0.1
to 10 mg/kg, 0.1 to 5 mg/kg or 0.1 to 1 mg/kg. In another
embodiment, the compounds of the invention can also be
administered for 5 days with a daily dose of0. 12 mg/kg. In yet
another embodiment, a single dose of 1.0 mg/kg to 10 mg/kg

or granules, suspensions or solutions in water or non-aqueous

media, capsules, sachets, or tablets. Thickeners, ?avorings,
50

administered to a subject comprising a human or an animal

including, but not limited to, a mouse, dog, cat, horse, bovine
55

can be administered.

The present invention also provides a method of treating

peutically in combination with a pharmaceutically acceptable

Paget’s Disease in a subject diagnosed with Paget’s Disease,

carrier. Pharmaceutical carriers are known to those skilled in
60

administration of compositions to humans and non-humans,
including solutions such as sterile water, saline, and buffered
solutions at physiological pH. Other compounds will be
administered according to standard procedures used by those
skilled in the art.

or bovine and the like, that is in need of alleviation or ame

lioration from a recognized medical condition.

Any of the compounds of the invention can be used thera

the art. These most typically would be standard carriers for

diluents, emulsi?ers, dispersing aids or binders may be desir
able.
In one embodiment, the compounds of the invention are

comprising administering to the subject an effective amount
of a compound of the invention, whereby the compound treats
the Paget’s Disease in the subject. The subject can be a mam
mal, preferably a human, and the compound is administered

parenterally.
Further provided by the present invention is a method of
65

treating hypercalcemia in a subject diagnosed with hypercal

Any of the compounds of the invention intended for phar

cemia, comprising administering to the subject an effective

maceutical delivery may be formulated in a pharmaceutical

amount of a compound of the invention in a pharmaceutically

US 7,423,008 B2
24

23
acceptable carrier, whereby the compound treats hypercalce
mia in the subject. The subject can be a mammal, preferably
a human, and the compound is administered parenterally.
The present invention also provides a method of providing

neuroprotection in subject diagnosed With neurological dis
eases, the method comprising the step of administering to the
subject an effective amount of a compound of the invention in

a pharmaceutically acceptable carrier, Whereby the com

pound provides neuroprotection in the subject. The subject
can be a mammal, preferably a human, and the compound is

administered parenterally.
The present invention also provides a method of providing

neuroprotection in subject diagnosed With neurological dis
eases, the method comprising the step of administering to the

The compounds of the invention can be useful as a bio

chemical tool. For example, the compounds can be useful to

block the c-Src (and other Spl-dependent enzymes) expres
sion in osteoclast or other cells.
It Will be apparent to those skilled in the art that various
modi?cations and variations can be made in the present

invention Without departing from the scope or spirit of the
invention. Other embodiments of the invention Will be appar
ent to those skilled in the art from consideration of the speci
?cation and practice of the invention disclosed herein. It is
intended that the speci?cation and examples be considered as
exemplary only, With a true scope and spirit of the invention

being indicated by the folloWing claims.
This invention is not limited to speci?c synthetic methods,

subject an effective amount of a compound of the invention in 15 speci?c compositions, or to particular formulations, as such
a pharmaceutically acceptable carrier, Whereby the commay, of course, vary. It is also to be understood that the

pound provides neuroprotection in the subject. The subject

terminology used herein is for the purpose of describing

can be a mammal, preferably a human, and the compound is

particular embodiments only and is not intended to be limit

administered parenterally.

ing.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS:

1

<211> LENGTH: 5975
<212> TYPE: DNA

<2l3> ORGANISM: Streptomyces argillaceus
<4oo> SEQUENCE:

1

ggatcctcgt ccgtctcgac caccaggtag cggctcagcg cccggtagaa acggccgccc

60

tcctcggact gcacggcgtc gtagaggatc tgctccggcc gggccgcgag cacctggtcc

120

aggaacctgg gccgctgttc gggggggaga tgagcgtggt cgtcggggac gcactggacg

180

gtcggggcca gctcgatgag gtcgacgtag cccggttccg ggtgggcgcg cgccaggacg

240

tggaggacgc cgtcgatccg cttggccagg aacgccacca ccccggtgcc gcgcgggctg

300

agcagcggct gggtccaccc cttgacttcg cggttgccgg cctccacaga cacggcgacg

360

atcgcgaagt gccgtccact ggtgtggcgt atctcgtccg tgtcgcggac ccagccgtcc

420

acggaggtca gcgggacgag ctgcgcggcg acctcgctgc gcgccctgag cccgttgaac

480

cagcgcagca gctcgggcag ggtgtgcgcg gcgggggcct gcgcggacag ggaggcggtc

540

agggcggcca cggccgcccc gcgggaaccg tcggtcgtga ctccctcgag ggaaccgtcc

600

ggcggggcga cggggaggca ggccaggacc gtccgagtgt ccatgttgac caggtccggg

660

acgccgagca gccggcggac ctgaccgagg gtcagccagc ggtagtcctc gtgctcgggc

720

acgtcgccga cggcctcgac gacgagattg cggttgcgtt tgcggaagaa ccaggaaccg

780

tgctcggact ggagcacgtc gaccagcggc cggcccttgc cggggtccgt gaagtactcc

840

aggtaccgca cggcgctgcc ctcgtgcacg cccgtgtagt tgctgcgggt ggcctgcacc

900

gtgggcgaca actggagtcc ctcggcgttg ccgggctcgg ccttcgcctg catcaggcag

960

tgcaggacac cgtcgaactc cttgaccagg atgccgagga aacccacttc cggctggtgc

1020

atgatcggct gggaccagga gacggggtcc gggccctcgg agcgagcccg cagcccttcg

1080

acggtgaaga agcggccgct gtcgtgcgcc agattcccgg tgaccgggtg gaagccccag

1140

cgctggagct cggcgaaggg gatgcgcctc acgtccatcc ggatggcctt gcggcgctcc

1200

tcgaaccagt cgtggacacc acccagggac agcagtccgc tgtcggccgc cgccgattcg

1260

